Pharmacy Times

JUNE 25, 2025

Updated January 22, 2020. link] Newsletter Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights. months versus 7.79 months with tislelizumab. months versus 7.79 months with tislelizumab. Accessed June 25, 2025.

Chemotherapy 20

Chemotherapy Pharmacy Technician Immunity Immunization 20

Pharmacy Times

JULY 15, 2025

Carey: We know that medication management is a troubling problem, and that's really in part because patients can experience a barrier during any point of their medication journey. Common barriers that I think of include access and cost, but also treatment complexity and forgetfulness.

Pharmacy Technician 26

Pharmacy Technician Diabetes Biosimilars Compounding Pharmacies 26

Pharmacy Times

JULY 8, 2025

1 Interestingly, there were similar rates of biosimilar initiation by age group every year except for 2020 ( p =.03), 03), which the authors deduced was likely because of the small number of patients initiating anti-TNFs in the under 6 years age group (n = 17) in 2020.

Biosimilars 40

Biosimilars HIV Treatment and Prevention Agents Pharmacy Technician Compounding Pharmacies 40

Pharmacy Times

JULY 18, 2025

Updated May 6, 2020. link] Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act Guidance for Industry, January 2018. Accessed June 9, 2025. link] FDA Drug Shortages. Updated December 19, 2024. Accessed June 9, 2025.

Compounding 29

Compounding Pharmacy Technician Compounding Pharmacies Documentation 29

Pharmacy Times

JULY 1, 2025

Using data from the National Cancer Database, they performed a retrospective analysis on patients diagnosed with metastatic HR–/HER2+ breast cancer between January 2013 and December 2020. The patients were assigned to 1 of 2 groups: those who received HER2-targeting therapies and those who did not. 3 Among the patients, approximately 75.8%

Pharmacy Technician 40

Pharmacy Technician Compounding Pharmacies Pharmacy Management Immunity 40

Pharmacy Times

JUNE 30, 2025

Supreme Court’s decision not to review a pharmacy benefit manager reform case out of Oklahoma: “After the historic Rutledge v. Douglas Hoey on the U.S.

Pharmacy Technician 26

Pharmacy Technician Community Pharmacies Compounding Pharmacies Immunity 26

Pharmacy Times

JUNE 18, 2025

PTCy recipients included those who received peripheral blood stem cells of haploidentical-related and mismatched unrelated donor transplants.

Pharmacy Technician 29

Pharmacy Technician Compounding Pharmacies Dosage Pharmacy Management 29

Pharmacy Times

JUNE 11, 2025

Image credit: marilyn barbone | stock.adobe.com Pharmacists as Key Players in Cardiovascular Treatment Plans Pharmacists are already crucial in managing medications for conditions like hypertension, hyperlipidemia, diabetes, and heart failure—all of which are significant risk factors for CVD.

Pharmacy Technician 32

Pharmacy Technician Diabetes Compounding Pharmacies Grocery Stores 32

The Happy PharmD

JUNE 27, 2022

In one of such studies by Drug Topics® in 2020, 7 out of 10 pharmacists revealed they were not happy with their jobs. In a similar survey done in 2020, 42% of 217 pharmacists said they were happy at work. It, therefore, means that pharmacy management in retail, clinical setting, or pharma has a crucial role in preventing burnout.

Packaging 52

Packaging Pharmacy Management Diabetes Hospitals 52

Digital Pharmacist

MARCH 23, 2023

Between 2010 and 2020, CMS reported (§ 423.100) that retroactive DIR fees increased by an astonishing 107,400%. Pharmacy Performance Metrics Medication Adherence: Non-adherence to three chronic disease categories — oral diabetes medications, statins for cholesterol, and hypertension medications — impacts a pharmacy’s adherence score.

Medication Therapy Management (MTM) 52

Medication Therapy Management (MTM) Mail-Order Pharmacies Diabetes HIPAA 52

Pharmacy Times

JUNE 27, 2025

August 5, 2020. Study of single agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone (Pom/​Dex) in participants with relapsed/​refractory multiple myeloma (RRMM) (DREAMM-3). Updated June 10, 2025. Accessed June 27, 2025. FDA granted accelerated approval to belantamab mafodotin-blmf for multiple myeloma.

Pharmacy Technician 26

Pharmacy Technician Diabetes Hospitals Compounding Pharmacies 26